XML 18 R11.htm IDEA: XBRL DOCUMENT
v3.24.3

Product Revenues, Accounts Receivable, and Reserves for Product Sales | 9 Months Ended
--- | ---
Sep. 30, 2024
Product Revenues Accounts Receivable And Reserves For Product Sales [Abstract] |
Product Revenues, Accounts Receivable, and Reserves for Product Sales | 3. Product Revenues, Accounts Receivable, and Reserves for Product Sales The Company received FDA approval for the sale of EMPAVELI in the United States in May 2021 and approval for the sale of SYFOVRE in the United States in February 2023. The Company’s product revenues consist of sales of EMPAVELI and SYFOVRE to specialty pharmacies and specialty distributors. The table reflects product revenue by major source for the following periods (in thousands):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Products: |  |  |  |  |  |  |  |  |  |  |  |
EMPAVELI |  | $ | 24,611 |  |  | $ | 23,901 |  |  | $ | 74,733 |  |  | $ | 66,643 |
SYFOVRE |  |  | 151,960 |  |  |  | 75,281 |  |  |  | 444,049 |  |  |  | 160,983 |
Total Product revenue, net |  | $ | 176,571 |  |  | $ | 99,182 |  |  | $ | 518,782 |  |  | $ | 227,626 |
The Company’s accounts receivable balance of $279.0 million as of September 30, 2024 and $206.4 million as of December 31, 2023, consisted of EMPAVELI and SYFOVRE product sales receivable and licensing and other revenue receivables from our collaboration with Swedish Orphan Biovitrum AB (“Sobi”). The Company does not have a reserve related to expected credit losses against its receivable balance and expects to collect its accounts receivable in the ordinary course of business. The Company’s product revenue allowance and reserves totaled $32.9 million and $16.6 million as of September 30, 2024 and December 31, 2023, respectively. These amounts are included in accrued expenses on the Company’s unaudited condensed consolidated balance sheets. The following table summarizes activity in each of the product revenue allowance and reserve categories for the three and nine months ended September 30, 2024 (in thousands):
|  | Chargebacks, Discounts, and Fees |  |  | Government and Other Rebates |  |  | Returns |  |  | Total |
Ending balance at December 31, 2023 |  | $ | 5,674 |  |  | $ | 8,898 |  |  | $ | 2,053 |  |  | $ | 16,625 |
Provision related to sales in the current year |  |  | 9,575 |  |  |  | 13,125 |  |  |  | 1,355 |  |  |  | 24,055 |
Adjustments related to prior period sales |  |  | 146 |  |  |  | (19 | ) |  |  | (96 | ) |  |  | 31 |
Credits and payments made |  |  | (9,724 | ) |  |  | (9,906 | ) |  |  | (1,859 | ) |  |  | (21,489 | )
Ending balance at March 31, 2024 |  | $ | 5,671 |  |  | $ | 12,098 |  |  | $ | 1,453 |  |  | $ | 19,222 |
Provision related to sales in the current year |  |  | 10,025 |  |  |  | 17,777 |  |  |  | 1,039 |  |  |  | 28,841 |
Adjustments related to prior period sales |  |  | (131 | ) |  |  | 354 |  |  |  | (983 | ) |  |  | (760 | )
Credits and payments made |  |  | (9,635 | ) |  |  | (14,640 | ) |  |  | (326 | ) |  |  | (24,601 | )
Ending balance at June 30, 2024 |  | $ | 5,930 |  |  | $ | 15,589 |  |  | $ | 1,183 |  |  | $ | 22,702 |
Provision related to sales in the current year |  |  | 11,455 |  |  |  | 25,364 |  |  |  | 1,380 |  |  |  | 38,199 |
Adjustments related to prior period sales |  |  | 2,332 |  |  |  | 420 |  |  |  | — |  |  |  | 2,752 |
Credits and payments made |  |  | (12,078 | ) |  |  | (17,695 | ) |  |  | (979 | ) |  |  | (30,752 | )
Ending balance at September 30, 2024 |  | $ | 7,639 |  |  | $ | 23,678 |  |  | $ | 1,584 |  |  | $ | 32,901 |
The following table summarizes activity in each of the product revenue allowance and reserve categories for the three and nine months ended September 30, 2023 (in thousands):
|  | Chargebacks, Discounts, and Fees |  |  | Government and other rebates |  |  | Returns |  |  | Total |
Ending balance at December 31, 2022 |  | $ | 164 |  |  | $ | 1,936 |  |  | $ | 251 |  |  | $ | 2,351 |
Provision related to sales in the current year |  |  | 1,466 |  |  |  | 2,566 |  |  | 651 |  |  |  | 4,683 |
Adjustments related to prior period sales |  |  | — |  |  |  | (2 | ) |  |  | (249 | ) |  |  | (251 | )
Credits and payments made |  |  | (184 | ) |  |  | (1,639 | ) |  |  | — |  |  |  | (1,823 | )
Ending balance at March 31, 2023 |  | $ | 1,446 |  |  | $ | 2,861 |  |  | $ | 653 |  |  | $ | 4,960 |
Provision related to sales in the current year |  |  | 3,944 |  |  |  | 5,114 |  |  |  | 1,588 |  |  |  | 10,646 |
Adjustments related to prior period sales |  |  | (84 | ) |  |  | 30 |  |  |  | (416 | ) |  |  | (470 | )
Credits and payments made |  |  | (1,668 | ) |  |  | (2,946 | ) |  |  | (141 | ) |  |  | (4,755 | )
Ending balance at June 30, 2023 |  | $ | 3,638 |  |  | $ | 5,059 |  |  | $ | 1,684 |  |  | $ | 10,381 |
Provision related to sales in the current year |  |  | 4,698 |  |  |  | 7,169 |  |  |  | 1,384 |  |  |  | 13,251 |
Adjustments related to prior period sales |  |  | 39 |  |  |  | (964 | ) |  |  | (1,685 | ) |  |  | (2,610 | )
Credits and payments made |  |  | (4,960 | ) |  |  | (5,778 | ) |  |  | — |  |  |  | (10,738 | )
Ending balance at September 30, 2023 |  | $ | 3,415 |  |  | $ | 5,486 |  |  | $ | 1,383 |  |  | $ | 10,284 |
Significant customers - EMPAVELI and SYFOVRE are sold principally through arrangements with specialty pharmacies and specialty distributors, who are the Company’s customers. Gross product revenues and product sales receivable from the Company's customers who individually accounted for 10% or more of total gross product revenues and/or 10% or more of total product sales accounts receivable consisted of the following:
|  | Percent of Total Gross Product Revenues
|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
|  | 2024 |  | 2023 |  | 2024 |  | 2023
Customer A |  | 12% |  | 24% |  | 13% |  | 29%
Customer C |  | 17% |  | 16% |  | 18% |  | 14%
Customer D |  | 61% |  | 56% |  | 59% |  | 52%
|  | Percent of Product Sales Receivable
|  | As of September 30,
|  | 2024 |  | 2023
Customer A |  | 3% |  | 7%
Customer C |  | 24% |  | 19%
Customer D |  | 61% |  | 68%
Factoring of accounts receivable and associated fees as of September 30, 2024 and December 31, 2023 were as follows (in thousands):
|  | September 30, |  |  | December 31, |
|  | 2024 |  |  | 2023 |
Accounts receivable sold |  | $ | 56,590 |  |  | $ | — |
Less: factoring fees |  |  | (672 | ) |  |  | — |
Net cash proceeds |  | $ | 55,918 |  |  | $ | — |

X
- Definition Product revenues, accounts receivable, and reserves for product sales. + References No definition available. + Details
Name: | apls_ProductRevenuesAccountsReceivableAndReservesForProductSalesAbstract
Namespace Prefix: | apls_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Product revenues, accounts receivable, and reserves for product sales. + References No definition available. + Details
Name: | apls_ProductRevenuesAccountsReceivableAndReservesForProductSalesTextBlock
Namespace Prefix: | apls_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration